Predicted Trait | |
Reported Trait | High grade serous ovarian cancer |
Mapped Trait(s) | high grade ovarian serous adenocarcinoma (EFO_1001958) |
Score Construction | |
PGS Name | PRS_HGS |
Variants | |
Original Genome Build | GRCh37 |
Number of Variants | 22 |
Development Method | |
Name | Genome-wide significant SNPs |
Parameters | p<5e-8 |
PGS Source | |
PGS Catalog Publication (PGP) ID | PGP000117 |
Citation (link to publication) | Barnes DR et al. Genet Med (2020) |
Study Identifiers | Sample Numbers | Sample Ancestry |
---|---|---|
GWAS Catalog: GCST004480 EuropePMC: 28346442 |
53,978 individuals | European |
PGS Performance Metric ID (PPM ID) |
PGS Sample Set ID (PSS ID) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
PGS Classification Metrics | Other Metrics | Covariates Included in the Model | PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|
PPM001037 | PSS000532 | PGP000117 Barnes DR et al. (2020) |
Reported Trait: Incident ovarian cancer in BRCA2 carriers | HR: 1.45 [1.13, 1.86] | — | — | family history of the appropriate cancer in first- and second-degree relatives | — |
PPM001036 | PSS000530 | PGP000117 Barnes DR et al. (2020) |
Reported Trait: Incident ovarian cancer in BRCA1 carriers | HR: 1.28 [1.06, 1.55] | — | — | family history of the appropriate cancer in first- and second-degree relatives | — |
PPM001033 | PSS000528 | PGP000117 Barnes DR et al. (2020) |
Reported Trait: Ovarian cancer in BRCA2 carriers | HR: 1.43 [1.29, 1.59] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
PPM001032 | PSS000524 | PGP000117 Barnes DR et al. (2020) |
Reported Trait: Ovarian cancer in BRCA1 carriers | HR: 1.32 [1.25, 1.4] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
PGS Sample Set ID (PSS ID) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS000524 | — | — | [ ,
0.0 % Male samples |
— | European | — | 59 cohorts
|
— |
PSS000528 | — | — | [ ,
0.0 % Male samples |
— | European | — | 59 cohorts
|
— |
PSS000530 | To assess associationss between the PRS and ovarian cancer risk, eligibility was restricted to women who had not been diagnosed with ovarian cancer and had not had RRSO at the time of baselinne questionnaire completion. Carriers diagnosed with invasive ovarian, fallopian tube, or peritoneal cancer during the follow-up were considered affected. | — | [ ,
0.0 % Male samples |
— | European | — | 61 cohorts
|
— |
PSS000532 | To assess associationss between the PRS and ovarian cancer risk, eligibility was restricted to women who had not been diagnosed with ovarian cancer and had not had RRSO at the time of baseline questionnaire completion. Carriers diagnosed with invasive ovarian, fallopian tbe, or peritoneal cancer during the follow-up were considered affected. | — | [ ,
0.0 % Male samples |
— | European | — | 61 cohorts
|
— |